Tyrosine Kinase Domain Mutation Analysis
| Category | Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS) >> Molecular Pathology |
|---|---|
| Test background |
Mutations in the tyrosine kinase domain of BCR-ABL are the most common cause of resistance to the tyrosine kinase inhibitors (TKI) in CML patients. Therefore, early detection of these mutations will guide clinicians to a more appropriate course of treatment. Sanger sequencing can detect a range of mutations within the TK domain to the level of approximately 20% |
| Clinical Indications |
BCR-ABL1 positive patients that are relapsing or not responding to treatment. |
| Sample & container required | 20 mL peripheral blood or 3-5.0 mL bone marrow in EDTA (lavender top); 25uL of cDNA. |
| Transport storage | Samples must be less than 72 hours old upon receipt within the laboratory. Therefore, samples received after 3pm on a Friday will be rejected (unless they were taken on the same day). |
| Turnaround time | 21 calendar days |